Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema

NCT01826916 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01826916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01826916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema
Lead sponsor
Shire
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2003
Completion date
January 1, 2006
Enrollment
77 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)